Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sawai Pharmaceutical Co., Ltd.

https://www.sawai.co.jp/en/

Latest From Sawai Pharmaceutical Co., Ltd.

Chugai’s Eldecalcitol Challenge Fails In Japan

Chugai has seen its attack on Sawai and Nichi-Iko over their generic eldecalcitol rivals to the originator’s Edirol brand dismissed by a Tokyo district court.

Legal Issues Intellectual Property

Sawai’s Upsher-Smith Gets New Leadership Amid ‘Drastic Restructuring’

A major overhaul is in progress for Sawai’s Upsher-Smith business, after the Japanese parent company announced leadership changes and a “drastic restructuring” of the US unit in the wake of a significant impairment charge and a hefty annual operating loss that dragged down Sawai’s overall results.

Executive Changes Strategy

A Year's Struggle: How Japan Is Recovering Damaged Generic Supplies After Quality Violations

Japan struggles to recover its ever-expanding supply chain for generic drugs after several key players had their production stopped because of a series of GMP violations. As the share of generics grows under government policy, some in the industry argue the problems are deeply rooted in a decades-old pricing system.

Japan Generic Drugs

Too Fast, Too Much? Japan Cuts Prices By 6.7% As Annual Revisions Bite

The Japanese government will apply new drug reimbursement prices from 1 April, under which Pfizer’s Vyndaqel will be slashed by 75% and UCB's E Keppra by 26%. Nobelpharma and Santen will be also affected by the revision, which averages close to 7% across the board.

Japan Reimbursement
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Cambridge Biotechnology Ltd (CBT)
    • Minster Pharmaceuticals
    • Proximagen Group
    • Upsher-Smith Laboratories Inc.
    • Medisa Shinyaku Inc. and Kaken Shoyaku Inc.
UsernamePublicRestriction

Register